Skip to main content

Table 4 Cox regression analysis for disease-free and overall survival in postmenopausal patients

From: Tumour Fas ligand:Fas ratio greater than 1 is an independent marker of relative resistance to tamoxifen therapy in hormone receptor positive breast cancer

  Disease-free survival analysis Overall survival analysis
  Univariate Multivariate Univariate Multivariate
Variable P RR (95% CI) P RR (95% CI) P RR (95% CI) P RR (95% CI)
Grading 0.107 1.42 (0.93–2.17) - - 0.015 1.81 (1.12–2.91) 0.059 1.58 (0.98–2.56)
Lymph node status 0.05 1.97 (1.01–3.87) - - 0.134 1.83 (0.83–4.05) - -
Tumour size 0.001 1.85 (1.27–2.7) 0.003 1.79 (1.22–2.64) 0.001 2.11 (1.38–3.23) 0.002 1.97 (1.27–3.03)
ER status 0.774 1.12 (0.53–2.34) - - 0.903 0.95 (0.4–2.24) - -
PgR status 0.19 0.65 (0.34–1.23) - - 0.558 0.8 (0.37–1.7) - -
FasL : Fas ratio 0.01 2.29 (1.22–4.32) 0.028 2.04 (1.08–3.85) 0.187 1.65 (0.78–3.46) - -
  1. The analysis was conducted in 148 women. CI, confidence interval; ER, oestrogen receptor; FasL, Fas ligand; PgR, progesterone receptor; RR, relative risk.